Samples

Specimen ID: 343-992-9203-0

Control ID:

SAMPLE REPORT, 138370

Patient Details
DOB: 01/01/1980
Age(y/m/d): 040/11/07
Gender: F
Patient ID:

Specimen Details
Date collected: 12/08/2020 0000 Local
Date received: 12/08/2020
Date entered: 12/08/2020
Date reported: 12/08/2020 0000 ET

Physician Details
Ordering: 
Referring: 
ID: 
NPI:

General Comments & Additional Information
Clinical Info: NORMAL REPORT

Ordered Items
HSV Acyclovir Resistance

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV Acyclovir Resistance</td>
<td></td>
<td></td>
<td></td>
<td>Sensitive: &lt;2.00</td>
<td></td>
</tr>
<tr>
<td>ID 50 = A</td>
<td>&lt;0.25 ug/mL</td>
<td></td>
<td></td>
<td>Resistant: &gt;1.90</td>
<td></td>
</tr>
</tbody>
</table>

This isolate would be considered sensitive to Acyclovir. The concentration of drug which results in a 50% reduction in plaque formation induced by viral cytopathic effect (CPE) versus the no-drug control established the Inhibitory Dose 50 (ID 50) drug concentration. The range of drug concentration tested varies with respect to the type of drug.

Comments:
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

01 BN LabCorp Burlington
1447 York Court, Burlington, NC 27215-3361
Dir: Sanjai Nagendra, MD

For inquiries, the physician may contact Branch: 800-222-7566 Lab: 800-762-4344
**Clinical Info:** ABNORMAL REPORT

**Ordered Items**
HSV Acyclovir Resistance

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>HSV Acyclovir Resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID 50 = A</td>
<td>&gt;50.01</td>
<td></td>
<td>ug/mL</td>
<td></td>
<td>01</td>
</tr>
</tbody>
</table>

This isolate would be considered resistant to Acyclovir. The concentration of drug which results in a 50% reduction in plaque formation induced by viral cytopathic effect (CPE) versus the no-drug control established the Inhibitory Dose 50 (ID 50) drug concentration. The range of drug concentration tested varies with respect to the type of drug.

**Comments:**
^ This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.